Top

Published in:

Open Access 01-12-2012 | Research

Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy

Authors: Annette Raabe, Katharina Derda, Sebastian Reuther, Silke Szymczak, Kerstin Borgmann, Ulrike Hoeller, Andreas Ziegler, Cordula Petersen, Ekkehard Dikomey

Published in: Radiation Oncology | Issue 1/2012

Abstract

Purpose

To examine the association of polymorphisms in ATM (codon 158), GSTP1 (codon 105), SOD2 (codon 16), TGFB1 (position −509), XPD (codon 751), and XRCC1 (codon 399) with the risk of severe erythema after breast conserving radiotherapy.

Methods and materials

Retrospective analysis of 83 breast cancer patients treated with breast conserving radiotherapy. A total dose of 50.4 Gy was administered, applying 1.8 Gy/fraction within 42 days. Erythema was evaluated according to the Radiation Therapy Oncology Group (RTOG) score. DNA was extracted from blood samples and polymorphisms were determined using either the Polymerase Chain Reaction based Restriction-Fragment-Length-Polymorphism (PCR-RFL) technique or Matrix-Assisted-Laser-Desorption/Ionization –Time-Of-Flight-Mass-Spectrometry (MALDI-TOF). Relative excess heterozygosity (REH) was investigated to check compatibility of genotype frequencies with Hardy-Weinberg equilibrium (HWE). In addition, p-values from the standard exact HWE lack of fit test were calculated using 100,000 permutations. HWE analyses were performed using R.

Results

Fifty-six percent (46/83) of all patients developed erythema of grade 2 or 3, with this risk being higher for patients with large breast volume (odds ratio, OR = 2.55, 95% confidence interval, CI: 1.03–6.31, p = 0.041). No significant association between SNPs and risk of erythema was found when all patients were considered. However, in patients with small breast volume the TGFB1 SNP was associated with erythema (p = 0.028), whereas the SNP in XPD showed an association in patients with large breast volume (p = 0.046). A risk score based on all risk alleles was neither significant in all patients nor in patients with small or large breast volume. Risk alleles of most SNPs were different compared to a previously identified risk profile for fibrosis.

Conclusions

The genetic risk profile for erythema appears to be different for patients with small and larger breast volume. This risk profile seems to be specific for erythema as compared to a risk profile for fibrosis.

Available only for authorised users

Jung H, Beck-Bornholdt HP, Svoboda V, Alberti W, Herrmann T: Quantification of late complications after radiation therapy. Radiother Oncol 2001, 61: 233-246. 10.1016/S0167-8140(01)00457-1CrossRefPubMed

Ko C, Citrin D: Radiotherapy for the management of locally advanced squamous cell carcinoma of the head and neck. Oral Dis 2009, 15: 121-132. 10.1111/j.1601-0825.2008.01495.xPubMedCentralCrossRefPubMed

Baumann M, Herrmann T, Koch R, Matthiessen W, Appold S, Wahlers B, Kepka L, Marschke G, Feltl D, Fietkau R, et al.: Final results of the randomized phase III CHARTWEL-trial (ARO 97–1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011, 100: 76-85. 10.1016/j.radonc.2011.06.031CrossRefPubMed

Hatton M, Nankivell M, Lyn E, Falk S, Pugh C, Navani N, Stephens R, Parmar M: Induction chemotherapy and continuous hyperfractionated accelerated radiotherapy (chart) for patients with locally advanced inoperable non-small-cell lung cancer: the MRC INCH randomized trial. Int J Radiat Oncol Biol Phys 2011, 81: 712-718. 10.1016/j.ijrobp.2010.06.053CrossRefPubMed

Turesson I, Nyman J, Holmberg E, Oden A: Prognostic factors for acute and late skin reactions in radiotherapy patients. Int J Radiat Oncol Biol Phys 1996, 36: 1065-1075. 10.1016/S0360-3016(96)00426-9CrossRefPubMed

Safwat A, Bentzen SM, Turesson I, Hendry JH: Deterministic rather than stochastic factors explain most of the variation in the expression of skin telangiectasia after radiotherapy. Int J Radiat Oncol Biol Phys 2002, 52: 198-204. 10.1016/S0360-3016(01)02690-6CrossRefPubMed

Alsner J, Andreassen CN, Overgaard J: Genetic markers for prediction of normal tissue toxicity after radiotherapy. Semin Radiat Oncol 2008, 18: 126-135. 10.1016/j.semradonc.2007.10.004CrossRefPubMed

Andreassen CN, Alsner J: Genetic variants and normal tissue toxicity after radiotherapy: a systematic review. Radiother Oncol 2009, 92: 299-309. 10.1016/j.radonc.2009.06.015CrossRefPubMed

Quarmby S, Fakhoury H, Levine E, Barber J, Wylie J, Hajeer AH, West C, Stewart A, Magee B, Kumar S: Association of transforming growth factor beta-1 single nucleotide polymorphisms with radiation-induced damage to normal tissues in breast cancer patients. Int J Radiat Biol 2003, 79: 137-143.CrossRefPubMed

10.

Andreassen CN, Alsner J, Overgaard J, Herskind C, Haviland J, Owen R, Homewood J, Bliss J, Yarnold J: TGFB1 polymorphisms are associated with risk of late normal tissue complications in the breast after radiotherapy for early breast cancer. Radiother Oncol 2005, 75: 18-21. 10.1016/j.radonc.2004.12.012CrossRefPubMed

11.

De Ruyck K, Van Eijkeren M, Claes K, Bacher K, Vral A, De Neve W, Thierens H: TGFbeta1 polymorphisms and late clinical radiosensitivity in patients treated for gynecologic tumors. Int J Radiat Oncol Biol Phys 2006, 65: 1240-1248. 10.1016/j.ijrobp.2006.03.047CrossRefPubMed

12.

Giotopoulos G, Symonds RP, Foweraker K, Griffin M, Peat I, Osman A, Plumb M: The late radiotherapy normal tissue injury phenotypes of telangiectasia, fibrosis and atrophy in breast cancer patients have distinct genotype-dependent causes. Br J Cancer 2007, 96: 1001-1007. 10.1038/sj.bjc.6603637PubMedCentralCrossRefPubMed

13.

Kim SY, Han SW, Kim GW, Lee JM, Kang YM: TGF-beta1 polymorphism determines the progression of joint damage in rheumatoid arthritis. Scand J Rheumatol 2004, 33: 389-394. 10.1080/03009740410010344CrossRefPubMed

14.

Andreassen CN, Alsner J, Overgaard M, Sorensen FB, Overgaard J: Risk of radiation-induced subcutaneous fibrosis in relation to single nucleotide polymorphisms in TGFB1, SOD2, XRCC1, XRCC3, APEX and ATM–a study based on DNA from formalin fixed paraffin embedded tissue samples. Int J Radiat Biol 2006, 82: 577-586. 10.1080/09553000600876637CrossRefPubMed

15.

Damaraju S, Murray D, Dufour J, Carandang D, Myrehaug S, Fallone G, Field C, Greiner R, Hanson J, Cass CE, Parliament M: Association of DNA repair and steroid metabolism gene polymorphisms with clinical late toxicity in patients treated with conformal radiotherapy for prostate cancer. Clin Cancer Res 2006, 12: 2545-2554. 10.1158/1078-0432.CCR-05-2703CrossRefPubMed

16.

Barnett GC, Coles CE, Burnet NG, Pharoah PD, Wilkinson J, West CM, Elliott RM, Baynes C, Dunning AM: No association between SNPs regulating TGF-beta1 secretion and late radiotherapy toxicity to the breast: results from the RAPPER study. Radiother Oncol 2010, 97: 9-14. 10.1016/j.radonc.2009.12.006PubMedCentralCrossRefPubMed

17.

Martin S, Sydenham M, Haviland J, A’Hern R, Owen R, Bliss J, Yarnold J: Test of association between variant tgbeta1 alleles and late adverse effects of breast radiotherapy. Radiother Oncol 2010, 97: 15-18. 10.1016/j.radonc.2010.03.019CrossRefPubMed

18.

West C, Rosenstein BS, Alsner J, Azria D, Barnett G, Begg A, Bentzen S, Burnet N, Chang-Claude J, Chuang E, et al.: Establishment of a Radiogenomics Consortium. Int J Radiat Oncol Biol Phys 2010, 76: 1295-1296. 10.1016/j.ijrobp.2009.12.017CrossRefPubMed

19.

Chakravarti A: It’s raining SNPs, hallelujah? Nat Genet 1998, 19: 216-217. 10.1038/885CrossRefPubMed

20.

Cargill M, Altshuler D, Ireland J, Sklar P, Ardlie K, Patil N, Shaw N, Lane CR, Lim EP, Kalyanaraman N, et al.: Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet 1999, 22: 231-238. 10.1038/10290CrossRefPubMed

21.

Halushka MK, Fan JB, Bentley K, Hsie L, Shen N, Weder A, Cooper R, Lipshutz R, Chakravarti A: Patterns of single-nucleotide polymorphisms in candidate genes for blood-pressure homeostasis. Nat Genet 1999, 22: 239-247. 10.1038/10297CrossRefPubMed

22.

Zschenker O, Raabe A, Boeckelmann IK, Borstelmann S, Szymczak S, Wellek S, Rades D, Hoeller U, Ziegler A, Dikomey E, Borgmann K: Association of single nucleotide polymorphisms in ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with clinical and cellular radiosensitivity. Radiother Oncol 2010, 97: 26-32. 10.1016/j.radonc.2010.01.016CrossRefPubMed

23.

Andreassen CN, Alsner J, Overgaard M, Overgaard J: Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother Oncol 2003, 69: 127-135. 10.1016/j.radonc.2003.09.010CrossRefPubMed

24.

Jurinke C, Denissenko MF, Oeth P, Ehrich M, van den Boom D, Cantor CR: A single nucleotide polymorphism based approach for the identification and characterization of gene expression modulation using MassARRAY. Mutat Res 2005, 573: 83-95. 10.1016/j.mrfmmm.2005.01.007CrossRefPubMed

25.

Ziegler A, König I, Thompson J: Biostatistical aspects of genome-wide association studies. Biom J 2008, 50: 8-28. 10.1002/bimj.200710398CrossRefPubMed

26.

Borgmann K, Hoeller U, Nowack S, Bernhard M, Roper B, Brackrock S, Petersen C, Szymczak S, Ziegler A, Feyer P, et al.: Individual radiosensitivity measured with lymphocytes may predict the risk of acute reaction after radiotherapy. Int J Radiat Oncol Biol Phys 2008, 71: 256-264. 10.1016/j.ijrobp.2008.01.007CrossRefPubMed

27.

Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, Fiegler H, Shapero MH, Carson AR, Chen W, et al.: Global variation in copy number in the human genome. Nature 2006, 444: 444-454. 10.1038/nature05329PubMedCentralCrossRefPubMed

28.

Bentzen SM: Potential clinical impact of normal-tissue intrinsic radiosensitivity testing. Radiother Oncol 1997, 43: 121-131. 10.1016/S0167-8140(97)01899-9CrossRefPubMed

29.

Mackay RI, Hendry JH: The modelled benefits of individualizing radiotherapy patients’ dose using cellular radiosensitivity assays with inherent variability. Radiother Oncol 1999, 50: 67-75. 10.1016/S0167-8140(98)00132-7CrossRefPubMed

30.

Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, Rosenstein BS: Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose-volume effects. Int J Radiat Oncol Biol Phys 2010, 76: S145-S150. 10.1016/j.ijrobp.2009.08.076PubMedCentralCrossRefPubMed

31.

Hayes JD, McLellan LI: Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res 1999, 31: 273-300. 10.1080/10715769900300851CrossRefPubMed

32.

Lavin MF, Kozlov S: ATM activation and DNA damage response. Cell Cycle 2007, 6: 931-942. 10.4161/cc.6.8.4180CrossRefPubMed

33.

Liochev SI, Fridovich I: The effects of superoxide dismutase on H2O2 formation. Free Radic Biol Med 2007, 42: 1465-1469. 10.1016/j.freeradbiomed.2007.02.015CrossRefPubMed

34.

Chen J, Suter B: Xpd, a structural bridge and a functional link. Cell Cycle 2003, 2: 503-506. 10.4161/cc.2.6.558CrossRefPubMed

35.

Caldecott KW: XRCC1 and DNA strand break repair. DNA Repair (Amst) 2003, 2: 955-969. 10.1016/S1568-7864(03)00118-6CrossRef

36.

Barcellos-Hoff MH: How tissues respond to damage at the cellular level: orchestration by transforming growth factor-{beta} (TGF-{beta}). BJR Suppl 2005, 27: 123-127.CrossRef

37.

Ambrosone CB, Tian C, Ahn J, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Chang-Claude J: Genetic predictors of acute toxicities related to radiation therapy following lumpectomy for breast cancer: a case-series study. Breast Cancer Res 2006, 8: R40. 10.1186/bcr1526PubMedCentralCrossRefPubMed

38.

Isomura M, Oya N, Tachiiri S, Kaneyasu Y, Nishimura Y, Akimoto T, Hareyama M, Sugita T, Mitsuhashi N, Yamashita T, et al.: IL12RB2 and ABCA1 genes are associated with susceptibility to radiation dermatitis. Clin Cancer Res 2008, 14: 6683-6689. 10.1158/1078-0432.CCR-07-4389CrossRefPubMed

39.

Suga T, Ishikawa A, Kohda M, Otsuka Y, Yamada S, Yamamoto N, Shibamoto Y, Ogawa Y, Nomura K, Sho K, et al.: Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int J Radiat Oncol Biol Phys 2007, 69: 685-693. 10.1016/j.ijrobp.2007.06.021CrossRefPubMed

40.

Back M, Guerrieri M, Wratten C, Steigler A: Impact of radiation therapy on acute toxicity in breast conservation therapy for early breast cancer. Clin Oncol (R Coll Radiol) 2004, 16: 12-16. 10.1016/j.clon.2003.08.005CrossRef

41.

Fernando IN, Ford HT, Powles TJ, Ashley S, Glees JP, Torr M, Grafton D, Harmer CL: Factors affecting acute skin toxicity in patients having breast irradiation after conservative surgery: a prospective study of treatment practice at the Royal Marsden Hospital. Clin Oncol (R Coll Radiol) 1996, 8: 226-233. 10.1016/S0936-6555(05)80657-0CrossRef

42.

Freedman GM, Anderson PR, Li J, Eisenberg DF, Hanlon AL, Wang L, Nicolaou N: Intensity modulated radiation therapy (IMRT) decreases acute skin toxicity for women receiving radiation for breast cancer. Am J Clin Oncol 2006, 29: 66-70. 10.1097/01.coc.0000197661.09628.03CrossRefPubMed

43.

Neal AJ, Torr M, Helyer S, Yarnold JR: Correlation of breast dose heterogeneity with breast size using 3D CT planning and dose-volume histograms. Radiother Oncol 1995, 34: 210-218. 10.1016/0167-8140(95)01521-HCrossRefPubMed

44.

Burri RJ, Stock RG, Cesaretti JA, Atencio DP, Peters S, Peters CA, Fan G, Stone NN, Ostrer H, Rosenstein BS: Association of single nucleotide polymorphisms in SOD2, XRCC1 and XRCC3 with susceptibility for the development of adverse effects resulting from radiotherapy for prostate cancer. Radiat Res 2008, 170: 49-59. 10.1667/RR1219.1CrossRefPubMed

45.

Popanda O, Marquardt JU, Chang-Claude J, Schmezer P: Genetic variation in normal tissue toxicity induced by ionizing radiation. Mutat Res 2009, 667: 58-69. 10.1016/j.mrfmmm.2008.10.014CrossRefPubMed

46.

Becker T, Knapp M: A powerful strategy to account for multiple testing in the context of haplotype analysis. Am J Hum Genet 2004, 75: 561-570. 10.1086/424390PubMedCentralCrossRefPubMed

47.

Werbrouck J, De Ruyck K, Duprez F, Veldeman L, Claes K, Van Eijkeren M, Boterberg T, Willems P, Vral A, De Neve W, Thierens H: Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int J Radiat Oncol Biol Phys 2009, 73: 1187-1195. 10.1016/j.ijrobp.2008.08.073CrossRefPubMed

48.

Chang-Claude J, Popanda O, Tan XL, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Ambrosone CB: Association between polymorphisms in the DNA repair genes, XRCC1, APE1, and XPD and acute side effects of radiotherapy in breast cancer patients. Clin Cancer Res 2005, 11: 4802-4809. 10.1158/1078-0432.CCR-04-2657CrossRefPubMed

49.

Chang-Claude J, Ambrosone CB, Lilla C, Kropp S, Helmbold I, von Fournier D, Haase W, Sautter-Bihl ML, Wenz F, Schmezer P, Popanda O: Genetic polymorphisms in DNA repair and damage response genes and late normal tissue complications of radiotherapy for breast cancer. Br J Cancer 2009, 100: 1680-1686. 10.1038/sj.bjc.6605036PubMedCentralCrossRefPubMed

50.

Iannuzzi CM, Atencio DP, Green S, Stock RG, Rosenstein BS: ATM mutations in female breast cancer patients predict for an increase in radiation-induced late effects. Int J Radiat Oncol Biol Phys 2002, 52: 606-613. 10.1016/S0360-3016(01)02684-0CrossRefPubMed

51.

Appleby JM, Barber JB, Levine E, Varley JM, Taylor AM, Stankovic T, Heighway J, Warren C, Scott D: Absence of mutations in the ATM gene in breast cancer patients with severe responses to radiotherapy. Br J Cancer 1997, 76: 1546-1549. 10.1038/bjc.1997.593PubMedCentralCrossRefPubMed

52.

Weissberg JB, Huang DD, Swift M: Radiosensitivity of normal tissues in ataxia-telangiectasia heterozygotes. Int J Radiat Oncol Biol Phys 1998, 42: 1133-1136. 10.1016/S0360-3016(98)00295-8CrossRefPubMed

53.

Bremer M, Klopper K, Yamini P, Bendix-Waltes R, Dork T, Karstens JH: Clinical radiosensitivity in breast cancer patients carrying pathogenic ATM gene mutations: no observation of increased radiation-induced acute or late effects. Radiother Oncol 2003, 69: 155-160. 10.1016/j.radonc.2003.08.004CrossRefPubMed

Title: Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy
Authors: Annette Raabe
Katharina Derda
Sebastian Reuther
Silke Szymczak
Kerstin Borgmann
Ulrike Hoeller
Andreas Ziegler
Cordula Petersen
Ekkehard Dikomey
Publication date: 01-12-2012
Publisher: BioMed Central
Published in: Radiation Oncology / Issue 1/2012
Electronic ISSN: 1748-717X
DOI: https://doi.org/10.1186/1748-717X-7-65

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Association of single nucleotide polymorphisms in the genes ATM, GSTP1, SOD2, TGFB1, XPD and XRCC1 with risk of severe erythema after breast conserving radiotherapy

Abstract

Purpose

Methods and materials

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods and materials

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2012

Systematic evaluation of three different commercial software solutions for automatic segmentation for adaptive therapy in head-and-neck, prostate and pleural cancer

Radiotherapy for tumors of the stomach and gastroesophageal junction – a review of its role in multimodal therapy

Failure patterns and survival in patients with nasopharyngeal carcinoma treated with intensity modulated radiation in Northwest China: A pilot study

Computed tomography-guided permanent brachytherapy for locoregional recurrent gastric cancer

Hypofractionated radiotherapy for primary or secondary oligometastatic lung cancer using Tomotherapy

Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: Is it better than three dimensional conformal radiotherapy?